Quarterly report pursuant to Section 13 or 15(d)

Organization, Description of Business, Basis of Presentation, Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements (Tables)

v3.8.0.1
Organization, Description of Business, Basis of Presentation, Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements (Tables)
 3 Months Ended
Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Financial Statement Line Items Affected by Adoption of New Revenue Recognition Guidance
The following table presents the amounts by which each financial statement line item was affected by adopting the new revenue recognition guidance (in thousands):
 
 
Three Months Ended March 31, 2018
 
 
As Reported
 
ASC 606 Adjustments
 
Balances Without Adoption
Consolidated Statements of Operations and Other Comprehensive Loss
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
Biopharma Services
 
$
3,658

 
$
(307
)
 
3,351

Clinical Services
 
2,342

 
—

 
2,342

Discovery Services
 
1,667

 
(529
)
 
1,138

 
 
$
7,667

 
$
(836
)
 
$
6,831

Consolidated Balance Sheets
 
 
 
 
 
 
CURRENT LIABILITIES
 
 
 
 
 
 
Deferred revenue
 
 
 
 
 
 
Biopharma Services
 
$
1,625

 
$
(1,547
)
 
$
78

Clinical Services
 
—

 
—

 
—

Discovery Services
 
126

 
(126
)
 
—

 
 
$
1,751

 
$
(1,673
)
 
$
78

 
 
 
 
 
 
 
NON-CURRENT LIABILITIES
 
 
 
 
 
 
Deferred revenue
 
 
 
 
 
 
Biopharma Services
 
$
516

 
$
—

 
$
516

Clinical Services
 
—

 
—

 
—

Discovery Services
 
476

 
—

 
476

 
 
$
992

 
$
—

 
$
992

 
 
 
 
 
 
 
STOCKHOLDERS' EQUITY
 
 
 
 
 
 
Accumulated (deficit)
 
$
(141,799
)
 
$
1,673

 
$
(140,126
)
Assets and Liabilities Acquired in Business Acquisition
The estimated allocation of the purchase price as of August 15, 2017 consists of the following (in thousands):
Cash
 
$
544

Accounts receivable
 
905

Lab supplies
 
350

Prepaid expenses and other current assets
 
60

Fixed assets
 
765

Intangible assets
 
3,160

Goodwill
 
5,960

Accounts payable and accrued expenses
 
(913
)
Deferred revenue
 
(814
)
Deferred rent and other
 
(222
)
Obligations under capital leases
 
(76
)
Total purchase price
 
$
9,719

Business Acquisition, Pro Forma Information
The following table provides certain pro forma financial information for the Company as if the acquisition of vivoPharm discussed above occurred on January 1, 2017 (in thousands except per share amounts):
 
Three Months Ended March 31,
 
2017
Revenue
$
8,134

Net loss
(9,795
)
 
 
Basic and dilutive net loss per share
$
(0.45
)